Today: 21 April 2026
Why Intuit Inc Stock Fell Despite a Fresh Upgrade as Tax Season Heats Up
10 March 2026
1 min read

Why Intuit Inc Stock Fell Despite a Fresh Upgrade as Tax Season Heats Up

NEW YORK, March 10, 2026, 2:47 PM EDT

Intuit shares dropped roughly 3.9% Tuesday, despite a fresh “buy” rating from Rothschild & Co Redburn’s Omar Sheikh. The stock was sitting near $455 in the afternoon, after Redburn bumped its target to $700 from the previous $670. StreetInsider.com

For Intuit, the April quarter usually delivers the biggest boost, thanks to U.S. tax season. But just last month, the company flagged adjusted third-quarter earnings between $12.45 and $12.51 a share—coming in shy of Wall Street’s forecasts—as it ramps up marketing and customer support spending before the April 15 tax deadline.

Redburn sounded more optimistic than the shares suggested. Analysts highlighted QuickBooks and TurboTax as standout picks when it comes to software that can weather AI headwinds, citing Intuit’s access to deep data, tangled tax and accounting regulations, and a loyal customer base that’s tough to pry away. That should give Intuit the muscle to maintain its pricing and deliver growth, the firm wrote.

Intuit’s January quarter numbers came in strong: revenue jumped 17% to $4.65 billion, and adjusted earnings hit $4.15 per share. CEO Sasan Goodarzi said the company is “defining a new category at the intersection of AI and human intelligence.” CFO Sandeep Aujla echoed that optimism, sticking with the outlook for double-digit revenue gains and fatter profit margins this year. Intuit Inc.

AI has become the linchpin of that strategy. Back on Feb. 24, Intuit announced a multi-year deal with Anthropic aimed at rolling out tailored AI agents for mid-sized companies, and integrating its tax, finance, and marketing software with Claude. Aujla noted that Intuit’s AI agents — essentially automated tools handling chores for users — are already being used by over 3 million customers.

Tax filing isn’t the only battleground. Last month, Reuters pointed out that Intuit faces off with H&R Block in the tax prep arena. The same story noted that in January, software stocks like Adobe and Salesforce took a hit—investors worried that fresh AI offerings might chip away at established subscription models.

The shadow of that broader concern hasn’t gone away. In a February note, JPMorgan’s Dubravko Lakos-Bujas and his team said the market had baked in “worst-case AI disruption scenarios” for software stocks—outcomes they argued were unlikely within the coming three to six months. Reuters

Still, not everything’s settled. Intuit warned that Mailchimp probably won’t hit double-digit growth again until after fiscal 2026, and it pointed to ongoing threats—competition, changing tax rules, and how well its AI-driven products actually work. Its reach is big, with about 100 million users split between TurboTax, QuickBooks, Credit Karma, and Mailchimp. That didn’t keep shares from sliding Tuesday, as investors pressed for firmer evidence that a strong tax season and fresh AI partnerships will do more than nudge revenue—they want to see real profit gains.

Stock Market Today

  • Earnings Boost U.S. Stock Futures as Ceasefire Deadline Approaches
    April 21, 2026, 12:07 PM EDT. U.S. stock futures rose ahead of the trading day after Wall Street's historic losing streak ended. UnitedHealth Group and RTX beat earnings expectations, with UNH shares up 7.9% premarket after a strong quarterly report and raised guidance. Apple shares dipped 0.4% following CEO Tim Cook's announcement of his departure in September. GE Aerospace shares fell over 4% despite beating earnings, citing concerns over rising fuel costs affecting flight volumes. Investors await Federal Reserve chair nominee Kevin Warsh's hearing and the U.S.-Iran ceasefire deadline tonight. Asian markets mostly gained, led by South Korea's Kospi hitting a record high, while European stocks remained cautious amid geopolitical uncertainty.

Latest article

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

21 April 2026
Eli Lilly will acquire Boston-based Kelonia Therapeutics for up to $7 billion in cash, including $3.25 billion upfront, to expand into in vivo CAR-T cancer therapies. Kelonia’s KLN-1010, in Phase 1 for multiple myeloma, generates engineered T-cells inside the patient. The deal marks Lilly’s third Massachusetts biotech purchase in 2026. Kelonia had 62 employees and nearly ran out of cash before the offer.
POET Technologies Stock Soars Again as PFIC Tax Clarity Eases Short-Seller Fears

POET Technologies Stock Soars Again as PFIC Tax Clarity Eases Short-Seller Fears

21 April 2026
POET Technologies shares surged 20% Tuesday, following an 18% gain Monday, after the company addressed U.S. shareholder tax concerns and announced plans to redomicile. Nearly 32.9 million shares traded by 10:21 a.m. ET, with the stock reaching $11.07 before settling at $10.34. Wolfpack Research disclosed a short position last week, sparking volatility. CFO Thomas Mika said POET expects not to qualify as a PFIC in 2026.
Why Rocket Lab Stock Is Rising Again as Analysts Lift Targets and Golden Dome Spending Comes Into Focus

Why Rocket Lab Stock Is Rising Again as Analysts Lift Targets and Golden Dome Spending Comes Into Focus

21 April 2026
Rocket Lab shares rose 2% to $91.12 Tuesday after analysts raised price targets and the Pentagon detailed new space defense spending in its 2027 budget request. The company closed its $155 million Mynaric acquisition last week and reported a $190 million Pentagon launch contract in March, bringing its backlog above $2 billion. Rocket Lab now expects to launch its Neutron rocket in late 2026 after a test setback.
BlackRock warns Middle East supply shock may lift inflation, but sees weeks-long disruption
Previous Story

BlackRock warns Middle East supply shock may lift inflation, but sees weeks-long disruption

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial
Next Story

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

Go toTop